Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carisbamate SCHEMBL2425732 | 1.00 | AOC3 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Carisbamate SCHEMBL1037665 | 1.00 | AOC3 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Carisbamate SCHEMBL8741032 | 0.95 | ADRB2 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Carisbamate SCHEMBL8741086 | 0.95 | ADRB2 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL13001768 | 0.83 | CASP1 (0.49) | AOC3CYP1A2CYP2D6CASP1ADRB2 | |
| SCHEMBL10216882 | 0.83 | CYP1A2 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL14200056 | 0.83 | CASP1 (0.49) | AOC3CYP1A2CYP2D6CASP1ADRB2 | |
| SCHEMBL14200054 | 0.83 | CASP1 (0.49) | AOC3CYP1A2CYP2D6CASP1ADRB2 | |
| SCHEMBL13879248 | 0.82 | CASP1 (0.48) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Hydrochloric Acid SCHEMBL3446916 | 0.82 | CYP1A2 (0.47) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021060998-A1 | PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY, AND THE USE OF J05 ATC GROUP SUBSTANCES IN TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY | CHUPTYŚ CONTISSI, Janusz (PL) | 2021-04-01 | — | — | WO | claimed |
| EP-3797764-A1 | PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY, AND THE USE OF J05 ATC GROUP SUBSTANCES IN TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY | Janusz Chupty Contissi (PL) | 2021-03-31 | — | — | EP | claimed |
| US-10201519-B2 | Stabilized pediatric suspension of carisbamate | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-02-12 | — | — | US | claimed |
| US-20170112798-A1 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-04-27 | — | — | US | claimed |
| US-20160008476-A1 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-01-14 | — | — | US | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| US-9161913-B2 | Stabilized pediatric suspension of carisbamate | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-10-20 | — | — | US | claimed |
| CN-104840971-A | Stabilized pediatric suspension of carisbamate | SK BIOPHARMACEUTICALS CO LTD | 2015-08-19 | — | — | CN | claimed |
| EP-2214637-B1 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-05-08 | — | — | EP | claimed |
| US-20120309826-A1 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | EMBRECHTS Roger (BE) | 2012-12-06 | — | — | US | claimed |
| WO-2008063284-A2 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-29 | — | — | WO | claimed |
| WO-2008045391-A2 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-17 | — | — | WO | claimed |
| US-20080085930-A1 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | SK BIOPHARMACEUTICALS CO., LTD (KR) | 2008-04-10 | — | — | US | claimed |
| US-20080031866-A1 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-07 | — | — | US | claimed |
| WO-2007149827-A2 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-27 | — | — | WO | claimed |
| US-7132112-B2 | Transnasal anticonvulsive compositions and modulated process | SK CORPORATION (KR) | 2006-11-07 | — | — | US | claimed |
| CN-1200697-C | Transnasal anticonvulsive compositions and methods of modulation | SK CORP (KR) | 2005-05-11 | — | — | CN | claimed |
| US-20040028617-A1 | Transnasal anticonvulsive compositions and modulated process | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2004-02-12 | — | — | US | claimed |
| US-6627211-B1 | Vehicle containing alcohol, glycol and biological surfactant | SK CORPORATION (KR) | 2003-09-30 | — | — | US | claimed |
| CN-1364079-A | Transnasal anticonvulsive compositions and modulated process | SK CORP (JP) | 2002-08-14 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112798-A1 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | CARM1, MGAM, HCAR1 | AOC3 4302/4885CYP1A2 971/4885CYP2D6 91/4885 |
| US-20160008476-A1 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | HPD, HMBS, HCAR1 | AOC3 4378/4885CYP1A2 797/4885CYP2D6 73/4885 |
| US-20080031866-A1 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | OAT, GLS2, G6PD | AOC3 1822/4885CYP1A2 56/4885CYP2D6 28/4885 |
| US-20040028617-A1 | Transnasal anticonvulsive compositions and modulated process | NPC1L1, NR1H4, SLC10A1 | AOC3 3839/4885CYP1A2 359/4885CYP2D6 558/4885 |
| US-20120309826-A1 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | HPD, HMBS, HCAR1 | AOC3 4378/4885CYP1A2 797/4885CYP2D6 73/4885 |
| US-10201519-B2 | Stabilized pediatric suspension of carisbamate | CARM1, MGAM, HCAR1 | AOC3 4302/4885CYP1A2 971/4885CYP2D6 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.